Modeling heart failure in animal models for novel drug discovery and development

被引:11
作者
Janssen, Paul M. L. [1 ,2 ,3 ]
Elnakish, Mohammad T. [1 ,2 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Animal model; human heart failure; ischemia; hypertension; contraction; LEFT-VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION MODEL; CONTRACTILE DYSFUNCTION; ANGIOTENSIN-II; CARDIAC-FUNCTION; CANINE MODEL; IN-VIVO; FORCE; MOUSE; RAT;
D O I
10.1080/17460441.2019.1582636
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: When investigating drugs that treat heart diseases, it is critical when choosing an animal model for the said model to produce data that is translatable to the human patient population, while keeping in mind the principles of reduction, refinement, and replacement of the animal model in the research. Areas covered: In this review, the authors focus on mammalian models developed to study the impact of drug treatments on human heart failure. Furthermore, the authors address human patient variability and animal model invariability as well as the considerations that need to be made regarding choice of species. Finally, the authors discuss some of the most common models for the two most prominent human heart failure etiologies; increased load on the heart and myocardial ischemia. Expert opinion: In the authors' opinion, the data generated by drug studies is often heavily impacted by the choice of species and the physiologically relevant conditions under which the data are collected. Approaches that use multiple models and are not restricted to small rodents but involve some verification on larger mammals or on human myocardium, are needed to advance drug discovery for the very large patient population that suffers from heart failure.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [1] Animal models for modeling pancreatic cancer and novel drug discovery
    Bisht, Savita
    Feldmann, Georg
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (02) : 127 - 142
  • [2] Animal models for drug discovery in dystonia
    Jinnah, H. A.
    Richter, Angelika
    Mink, Jonathon W.
    Caldwell, Guy A.
    Caldwell, Kim A.
    Gonzalez-Alegre, Pedro
    Cookson, Mark R.
    Breakefield, Xandra O.
    Delong, Mahlon R.
    Hess, Ellen J.
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (01) : 83 - 97
  • [3] Small Animal Models of Heart Failure Development of Novel Therapies, Past and Present
    Patten, Richard D.
    Hall-Porter, Monica R.
    CIRCULATION-HEART FAILURE, 2009, 2 (02) : 138 - 144
  • [4] Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery
    Gao, Si
    Liu, Xue-ping
    Li, Ting-ting
    Chen, Li
    Feng, Yi-ping
    Wang, Yu-kun
    Yin, Yan-jun
    Little, Peter J.
    Wu, Xiao-qian
    Xu, Suo-wen
    Jiang, Xu-dong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (01): : 23 - 35
  • [5] Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery
    Si Gao
    Xue-ping Liu
    Ting-ting Li
    Li Chen
    Yi-ping Feng
    Yu-kun Wang
    Yan-jun Yin
    Peter J. Little
    Xiao-qian Wu
    Suo-wen Xu
    Xu-dong Jiang
    Acta Pharmacologica Sinica, 2024, 45 : 23 - 35
  • [6] Animal models of Kabuki syndrome and their applicability to novel drug discovery
    Mertens, Mareike
    Khalife, Leen
    Ma, Xiaoting
    Bodamer, Olaf
    EXPERT OPINION ON DRUG DISCOVERY, 2025, 20 (02) : 253 - 265
  • [7] Animal models for Niemann-Pick type C: implications for drug discovery & development
    Fog, Cathrine K.
    Kirkegaar, Thomas
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (05) : 499 - 509
  • [8] Developing animal models of Zika virus infection for novel drug discovery
    Yde Ohki, Cristine Marie
    Benazzato, Cecilia
    Russo, Fabiele Baldino
    Baleeiro Beltrao-Braga, Patricia Cristina
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (06) : 577 - 589
  • [9] Animal models of heart failure with preserved ejection fraction
    Conceicao, G.
    Heinonen, I.
    Lourenco, A. P.
    Duncker, D. J.
    Falcao-Pires, I.
    NETHERLANDS HEART JOURNAL, 2016, 24 (04) : 275 - 286
  • [10] Animal models of skin disease for drug discovery
    Avci, Pinar
    Sadasivam, Magesh
    Gupta, Asheesh
    De Melo, Wanessa C. M. A.
    Huang, Ying-Ying
    Yin, Rui
    Chandran, Rakkiyappan
    Kumar, Raj
    Otufowora, Ayodeji
    Nyame, Theodore
    Hamblin, Michael R.
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (03) : 331 - 355